This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects (STEPS)

This study has been completed.
Information provided by (Responsible Party):
Shire Identifier:
First received: November 25, 2008
Last updated: November 10, 2015
Last verified: January 2015
Teduglutide is an investigative medicine being evaluated as a possible treatment for people with parenteral nutrition (PN) dependent Short Bowel Syndrome (SBS). Teduglutide is similar to a protein the body makes. When people have SBS, their bodies do not make enough of the protein and they have trouble getting nutrients and fluids from the food they eat and drink. This study was designed to provide evidence of efficacy, safety, and tolerability of teduglutide 0.05 mg/kg daily in SBS subjects.

Condition Intervention Phase
Short Bowel Syndrome Drug: teduglutide Drug: placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome

Resource links provided by NLM:

Further study details as provided by Shire:

Primary Outcome Measures:
  • Responder [ Time Frame: Weeks 20 and 24 ]
    Comparison of subjects treated with teduglutide to placebo who achieve a 20 to 100% reduction from baseline in weekly parenteral nutrition/intravenous fluid (PN/I.V.) volume at weeks 20 and 24.

Secondary Outcome Measures:
  • Absolute Change in PN/I.V. Volume From Baseline to Last Time Point [ Time Frame: Week 0 to last visit when data was collected. ]
    Absolute change in the volume of PN/I.V. from baseline (Week 0) to the visit when the last data point was collected (week 4 through week 24, or earlier if the subject discontinued early).

Enrollment: 86
Study Start Date: November 2008
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Teduglutide
0.05 mg/kg/day sc dose of teduglutide
Drug: teduglutide
0.05 mg/kg/day sc injection for 24 weeks
Other Names:
  • ALX-0600
Placebo Comparator: Placebo
Matching subcutaneous dose of placebo to teduglutide
Drug: placebo
Matching daily subcutaneous dose of placebo to teduglutide for 24 weeks


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed and dated informed consent prior to any study-related procedures are performed
  • Men and women 18 years of age or older at the time of informed consent signing
  • Intestinal failure resulting in Short Bowel Syndrome
  • At least 12 months of continuous PN dependency
  • 12 weeks of clinical remission of Crohn's disease (CD) prior to dosing
  • PN required at least 3 times weekly
  • A stable PN volume for four weeks prior to dosing

Exclusion Criteria:

  • History of cancer or clinically significant lymphoproliferative disease with fewer than 5 years documented disease-free state
  • Participation in clinical study within 30 days for drug or 90 days for antibody
  • Use of native GLP-2 or human growth hormone (HGH) within 6 months of screening
  • Use of iv glutamine within 30 days prior to screening
  • Use of teduglutide
  • CD patients who have been treated with biological therapy within 6 months of screening
  • IBD patients who require chronic systemic immunosuppressant therapy
  • More than 4 SBS- or PN-related hospitalizations within 12 months of screening
  • Unplanned hospitalization within one month of screening
  • Pregnant or lactating women
  • Body weight > 88kg
  • Body mass index (BMI) < 15 kg/m2
  • Severe hepatic impairment or disturbed renal function
  • Female subjects who are not surgically sterile or postmenopausal or who are not using medically acceptable methods of birth control during and for 30 days after the treatment period
  • Not capable of understanding or not willing to adhere to the study visit schedules and other protocol requirements
  • Any condition or circumstance that is the investigator's opinion would put the subject at any undue risk, prevent completion of the study, or interfere with the analysis of the study results
  • Significant active, uncontrolled, untreated systemic diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00798967

  Show 35 Study Locations
Sponsors and Collaborators
Study Director: NPS Clinical Trials NPS Pharma
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Shire Identifier: NCT00798967     History of Changes
Other Study ID Numbers: CL0600-020
Study First Received: November 25, 2008
Results First Received: December 23, 2011
Last Updated: November 10, 2015

Keywords provided by Shire:
short bowel syndrome
parenteral nutrition

Additional relevant MeSH terms:
Short Bowel Syndrome
Pathologic Processes
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Postoperative Complications processed this record on September 21, 2017